Applications and prospects of targeted therapy for neuroblastoma

Jing Wang, Wei Yao, Kai Li

ABSTRACT

Background Neuroblastoma is an extremely malignant tumor in children. For advanced or recurrent cases, existing treatment modalities are limited and efficacy remains disappointing. With the improvement in understanding of molecular biology of neuroblastoma and the development of clinical trials of targeted drug therapy, a variety of targeted therapies for neuroblastoma have appeared.

Data sources All the recent literatures on targeted therapies of neuroblastoma on PubMed were searched and reviewed.

Results This article reviewed targeted therapies of neuroblastoma going through clinical trials and obtained preliminary results. The features, advantages and disadvantages of targeted radiation therapy, immunotherapy, gene and pathway molecular inhibitor and angiogenesis inhibitor were discussed.

Conclusion This study provides references for better understanding the current progress of targeted therapies for neuroblastoma.

INTRODUCTION

Neuroblastoma is an extremely malignant and aggressive childhood tumor, which is prone to distant metastasis. Despite the improvement of multimodal treatment regimens including induction chemotherapy and surgery, intensive consolidation chemotherapy, irradiation and autologous hematopoietic stem-cell rescue, the outcome for children with advanced or recurrent diseases has been improved only modestly. With the promotion of molecular biological research of neuroblastoma, a variety of targeted therapies have been developed for clinical trials, providing promising intervention therapies for high-risk neuroblastoma, especially for relapsed/refractory disease. In this review, we presented the current status and prospects of targeted therapies for neuroblastoma going through clinical trials and obtained preliminary results.

The significance of targeted therapy for neuroblastoma

About half of children with neuroblastoma have distant metastasis at the time of diagnosis. Multimodality approaches including inducing chemotherapy and surgery, consolidation chemotherapy with autologous hematopoietic stem-cell rescue, radiation therapy and immunotherapy provide the standard-of-care treatment strategy for high-risk neuroblastoma to date. More than 50% of patients diagnosed with high-risk neuroblastoma were either resistant to conventional chemotherapies or relapsed after treatment. Patients with recurrent or refractory neuroblastoma had particularly low survival rates according to an analysis of large registry-based results. The 5-year overall survival (OS) postrelapse was 20%, and the 5-year OS was only 8% for patients in stage 4 with postrelapse in a report from the International Neuroblastoma Risk Group project. In 35 phase I/II clinical trials (from August 2002 to January 2014) for recurrent/refractory neuroblastoma conducted by Children’s Oncology Group (COG), the 4-year OS was reported to be 20%±2%. The analysis of these trials showed that most patients with high-risk neuroblastoma did not continue to receive other treatments that beyond inducing chemotherapy due to insufficient response to chemotherapy. For example, in a randomized phase III trial conducted by HR-NBL1/SIOPEN, 51.5% of the high-risk patients failed to continue beyond induction therapy. Therefore, the development of novel agents is imperative.

Recurrent neuroblastomas usually harbor heavy mutational burden but reduced subclonal heterogeneity compared with primary tumors at diagnosis. In a retrospective study of 138 patients whose tumors had been sequenced at diagnosis, second-look surgery and relapse revealed a substantial mutational evolution during treatment and progression. A variety of mutated genes are targetable and promising. Remarkably, anaplastic lymphoma kinase (ALK) was the most commonly mutated gene at diagnosis and gained a higher frequency of aberrations in recurrent tumors. An enrichment of activating mutations in the RAS-MAPK pathway was also observed in tumors after
chemotherapy or at relapse. Therefore, targeted therapies have become a promising approach to treating patients with neuroblastoma (especially relapsed and refractory cases) and to improving the prognosis.

With the intensive study of the etiology of neuroblastoma, more and more targeted drugs have been introduced. Several new drugs have been tested in clinical trials or are currently being tested, which include targeted radiation therapy, targeted immunotherapy, gene and pathway molecular inhibitor and angiogenesis inhibitor. The following sections discuss these drugs in detail.

**Approaches to targeted therapies for neuroblastoma**

**Targeted radiation therapy**

Metaiodobenzylguanidine (MIBG) is a compound that can be combined with radioactive iodine (\(^{131}\)I) to deliver targeted radiation therapy. It is an analog of norepinephrine and was first used as a radioactive tracer for imaging of the adrenal medulla. Tumors cells derived from sympathetic nervous system tissues, such as neuroblastoma, express the norepinephrine transporter (encoded by SLC6A2 gene), which is thought to have high specificity and sensitivity to MIBG. MIBG labeled with \(^{131}\)I could make it radioactive, which could achieve the purpose of treatment by killing tumor cells. Several clinical trials have shown that the response rate to treatment can reach 37% by gradually increasing the frequency and cumulative dose of \(^{131}\)I-MIBG in neuroblastoma, and the MIBG therapy also showed high effectiveness and good tolerance. Now, \(^{131}\)I-MIBG is mainly applied to clinical treatment of high-risk, recurrent and refractory patients.

**Targeted immunotherapy**

**Anti-GD2 antibodies**

Disialoganglioside (GD2) is a b-series ganglioside and plays an essential role in embryonic development. GD2 is highly expressed on the surface of neuroblastoma tumor cells, whereas its expression in normal tissues is limited. What is more, interfering with GD2 expression has a significant antitumor effect making this surface glycolipid antigen an ideal target for immunotherapy of neuroblastoma. There are currently three types of clinically used GD2 antibodies: mouse monoclonal antibodies (mAb), human-mouse chimeric antibodies, and humanized antibody.

**Active immunotherapy**

Neuroblastoma cells can avoid the attack of T cells and natural killer (NK) cells by downregulating human leukocyte antigen and adhesion molecules. At the same time, its cell surface carries abundant gangliosides and sialic acid-containing sugars and proteins, making it even immunosuppressive. Therefore, it is of necessity to develop active immunotherapy of neuroblastoma, the most representative of which are anti-idiotype vaccine and bivalent ganglioside vaccine.

**Adaptive T-cell therapy**

Adaptive cell therapy refers to the therapy isolating a large number of tumor-specific lymphocytes (e.g., T-lymphocytes) and re-injecting them into the patient after genetic modification and in vitro culture. The high-risk group neuroblastoma mainly focuses on chimeric antigen receptor (CAR)-T-cell therapy. Adaptive cell therapies aiming at high-risk neuroblastoma mainly concentrate on CAR-T-cell therapy. CAR consists of a single-chain variable fragment (anti-GD2), a transmembrane domain and an extracellular domain of an inner domain. CAR connects tumor cell surface antigens and provides co-stimulatory signals to T cells, enabling T cells to directly recognize and kill tumor cells beyond the major histocompatibility complex presentation mechanism.

**Gene and pathway molecular inhibitor**

**ALK inhibitors**

ALK belongs to the insulin receptor protein-tyrosine kinase superfamily and is considered as an oncogene in human cancers. ALK aberrations in neuroblastoma include copy number variation (CNV), amplification and mutation. ALK copy number gain is approximately 15%–25% of neuroblastoma, amplification is seen in 4% of high-risk cases and mutation is found in 6%–10% of cases. The most common point mutations of ALK are R1275Q (43%), F1174L (30%) and F1245C (12%), which could induce autophosphorylation of the tyrosine kinase domain and abnormal activation of the ALK receptor. The results of preclinical studies confirmed that ALK was a promising therapeutic target, which had the following advantages and characteristics. First, ALK abnormalities can be inhibited by small-molecule blockers, which are easy to prepare and are convenient to apply. Second, abrogation of ALK was effective both in the wild-type and in the mutated neuroblastoma cells. Third, ALK alterations are usually associated with MYCN amplification. ALK is a transcriptional target of MYCN, whereas ALK activates transcription of MYCN in neuroblastoma cell lines. Therefore, ALK inhibitors also have a therapeutic effect on neuroblastoma in the high-risk cases with MYCN amplification.

**Targeting MYCN-dependent transcription and N-Myc protein stability**

The transcription factor MYCN belongs to the MYC family, which is a crucial for regulating cell proliferation, cell growth, cell differentiation and survival in embryonic central nervous system cells. The amplification of the MYCN gene is the most common focal gene mutation in sporadic neuroblastoma, and it is also a strong indicator of the poor prognosis. However, the MYCN gene is still difficult to serve as a direct therapeutic target. MYCN can be repressed by targeting the transcription process of MYCN as well as by reducing the stability of the N-Myc protein. For example, bromodomain and extra terminal (BET) inhibitor can inhibit BET family proteins, which are the transcription factors binding at the promoter.
of MYCN gene, and can suppress the transcription of MYCN. Small molecule inhibitor of Aurora-A kinase destroys Aurora-A kinase/N-Myc protein complex, maintaining neuroblastoma cell proliferation, destabilizing N-Myc protein to mediate tumor regression.

Pathway inhibitors

Aberrantly activated gene pathways are important drivers in the malignant progression of neuroblastoma. Aberrations of ALK also induce activation of multiple downstream signaling like phosphatidylinositol 3-kinase/protein kinase B/mammalian target (PI3K/AKT/mTOR) and Ras/mitogen-activated protein kinase (RAS-MAPK) signal transduction pathways. PI3K/AKT/mTOR pathway is a key intracellular signaling pathway for tumorigenesis, promoting cell growth, proliferation, metastasis, angiogenesis and glucose metabolism. Abnormal activation of this pathway is common in high-risk neuroblastoma. In recent years, several novel agents have been developed to inhibit the occurrence and progress of neuroblastoma by blocking different targets in the PI3K/AKT/mTOR pathway.

Angiogenesis inhibitor

Angiogenesis is a key process for the continuous growth and metastasis of neuroblastoma. To date, a large number of pro-angiogenic factors have been identified, whose complicated interaction induces angiogenesis in neuroblastoma, including vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), fibroblast growth factor 2 (FGF-2), transforming growth factor-α, platelet-derived growth factor A (PDGF-A), erythropoietin and angiopoietins. Expression of VEGF and VEGF receptor (VEGFR) was associated with high-risk and high-stage neuroblastoma, and these factors were sensitive targets to antiangiogenic therapy. Antiangiogenic agents include single-pathway inhibitors and multipathway inhibitors. For example, bevacizumab is a single-pathway antiangiogenic antibody against VEGF that inhibits the binding of VEGF to the receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2). Ponatinib and imatinib are novel inhibitors for multiple tyrosine kinases involved in angiogenesis including FGFRI–4, RET, PDGFR, c-KIT, FLT3, MEKK2 and the VEGFR 1 and 2.

Advantages and disadvantages of currently applied targeted agents

Advantages of targeted therapies

High specificity

Due to focusing on a certain target of neuroblastoma tumor cells, drugs usually have higher specificity. 3F8 was the earliest mouse mAb used to treat neuroblastoma, belonged to IgG3 and has a high affinity for GD2. Hu3F8 is a humanized mAb of 3F8, which has longer retention on the GD2-positive cell surface. Besides, GD2 idiotype vaccine induced GD2-specific humoral immune response against gangliosides on the surface of neuroblastoma cells in mice and specifically killed neuroblastoma cells. Eleven of 13 children exhibited an IgM and/or IgG antibody response against NeuGcGM3 in the phase I trial of the anti-idiotypic vaccine racotumomab. JQ1 is a BET inhibitor targeted BRD4 from the MYCN promoter, results in inhibition of MYCN transcription and leads to cell cycle arrest and apoptosis, which may be beneficial for patients with MYCN-amplified neuroblastoma.

Great antitumor activity

Various targeted drugs showed great antitumor activity. A retrospective analysis of 39 patients with recurrent or refractory neuroblastoma who were treated with 131I-MIBG monotherapy demonstrated an objective response rate (ORR) of 46%. The human-murine chimeric anti-GD2 antibody ch14.18 (dinutuximab) had the same complement-mediated cytotoxicity (CMC) potency and 50-fold to 100-fold higher antibody-dependent cell-mediated cytotoxicity (ADCC) compared with mouse mAb 14G2a. The humanized anti-GD2 mAb hu14.18 has enhanced ADCC and has reduced CMC compared with mouse mAb, with a great ORR of 61.5% when combining with chemotherapy, IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF) and infusion of NK cells. Phase I trial of third-generation CAR-T GD2-CAR3 showed an increment of circulating IL-15 levels as an expansion of GD2-CAR3T cells was observed. The significant expansion of CD45/CD33/CD11b/CD163+ bone marrow cells in all children indicated that GD2-CAR3 was effective in early antitumor responses.

Improved prognosis

A variety of targeted drugs improved the prognosis of patients with high-risk neuroblastoma, especially in targeted immunotherapies. A comprehensive therapy including 131I-MIBG could improve the prognosis of refractory neuroblastoma, with a 3-year OS of 62%±8% in the new approaches to neuroblastoma therapy phase II study. Compared with retinoic acid (RA) alone, anti-GD2 mAb ch14.18 combined with GM-CSF plus IL-2 and RA significantly improved 2-year progression-free survival (PFS) (66%±5% vs 46±5%, p=0.01) and OS (86%±4% vs 75±5%, p=0.02). In the phase I trial of a bivalent gangliosides vaccine combined with immunological adjuvant OPT-821 and β-glucan, the result showed astonishing antitumor activity with a 2-year event-free survival of 80%±10% and OS of 93%±6%. The combination of Aurora A kinase inhibitor MLN8237, irinotecan and temozolomide in phase I trial has shown the ORR of 31.8% and the 2-year PFS of 52.4%. The phase II trial has demonstrated antitumor activity (1-year PFS 34%) of combination, particularly in children with MYCN non-amplified neuroblastoma. The AKT inhibitor perifosine showed a 3-year PFS rate of 36% in a phase I trial in patients with relapsed/refractory neuroblastoma, and 9 of 27 children without MYCN amplification had a median PFS of 54 months. Multikinase angiogenesis inhibitor imatinib revealed the complete remission (CR) rate of 21% at the time of the first report and 10-year OS
of 12.5% in prolonged phase II study, suggesting imatinib is efficient in some subjects with relapsed/refractory neuroblastoma.

Less side effects
Targeted drugs usually have fewer side effects, which leads to better compliance and better clinical use. Hu14.18K322A is a humanized anti-GD2 mAb to 14G2a, which has a single point mutation (K322A) designed to prevent activation of the complement cascade, thus reducing complement-mediated pain and the possibility of allergic reaction. Dose-limiting grade 3 or 4 toxicities have included sensory neuropathy, serum sickness and posterior reversible encephalopathy syndrome. Grade 3 or 4 pain has been observed in most patients. Compared with anti-GD2 mAbs, the regimen including the bivalent gangliosides vaccine had advantages of no neuropathic pain. The common side effects of MIBG were myelosuppression and diarrhea, which showed a good application prospect. The ALK inhibitor crizotinib was well tolerated without evidence of cumulative toxic effects in its phase I consortium study of pediatric refractory solid tumors, with common side effects of mild nausea, mild vomiting and mild visual disturbances.

Disadvantages of targeted therapies
Limited antitumor activity
Although anti-GD2 immunotherapies showed good cytotoxicity against neuroblastoma, several targeted drugs such as gene and pathway inhibitors showed limited antitumor activity in early phase clinical trials. COG developed a phase I trial of crizotinib in children with refractory neuroblastoma. In this trial, only 1 of 11 children harboring ALK translocation had CR, 2 children remained SD and the remaining cases had progressive disease. The phase II trials of mTOR inhibitor temsirolimus demonstrated that the 1-year PFS rate of patients with relapsed/refractory neuroblastoma was only 24.7% of temsirolimus plus irinotecan/temozolomide, which was significantly lower than the efficacy of ch14.18 plus irinotecan/temozolomide with 1-year PFS rate of 76.5%. Moreover, the angiogenesis inhibitor bevacizumab combined with irinotecan and temozolomide did not improve the response rate of refractory neuroblastoma compared with irinotecan/temozolomide treatment in phase II study.

Drug resistance
The utility of some targeted drugs has been limited due to drug resistance and disease progression. ALK inhibitor is an example, and the early phase clinical trials of ALK inhibitor crizotinib showed high disease progression rate. Vitro studies revealed that cell lines of neuroblastoma harboring F1174 and F1245 mutated ALK increased ATP-binding affinity and reduced ability to competitively inhibit ATP, resulting in resistance. Another study found that no additional mutations or CNV occurred in ALK, whereas the level of tyrosine kinase receptor activation altered, with significantly increased EGFR phosphorylation in crizotinib-resistant neuroblastoma cell line. Besides, the study showed that activation of receptor tyrosine kinases and PI3K signaling promoted drug resistance of BET inhibitor in neuroblastoma, informing efficacious synergistic therapies.

Immunogenicity
Although several targeted immunotherapies have obtained good curative effects, they still have common shortcomings, one of which is immunogenicity. Previous studies have found the incidence of antидrug antibody was 70%–80% for human antimonus antibody (m3F8), 19%–21% for human antichimeric antibody (ch14.18) and 40% for human antihuman antibody (hu14.18K322A), which resulted in a faster elimination of antibodies from the body due to neutralizing antibodies and affected the half-life of antibodies in the body. Also, Surek and Ektomab are anti-GD2 trifunctional bispecific full-length antibodies, containing the Fab fragments to the GD2/GD3-specific antibody ME361 and the T cell-specific CD3 antigen, which recruit cytotoxic lymphocytes and target them towards GD2-positive tumors. Since they consist of mouse and rat original antibody fragments, the immunogenicity and specificity of them also limit the prospects of their utilization. In addition, ME361 antibodies display cross-reactivity to GD3, which may increase side effects by influencing healthy body tissues.

Difficult to penetrate tumor tissue
Adaptive cell therapy for neuroblastoma faces multiple hurdles, and the first is the difficulty in penetrating the tumor to discharge their cytotoxic function. Unlike the high level of migrating efficacy of CAR-T cells against hematological malignancies, solid tumors including neuroblastoma secrete chemokines, such as CXCL12 and CXCL5 which inhibit T-cell migration into the tumor regions. Besides, the abnormal vasculature hinders effective infiltration, and in the surrounding matrix and the physical barrier of tumors, immunosuppressive bone marrow cells can be attracted to the tumor microenvironment, thereby preventing T-cell infiltration. Solving these problems is a major challenge for CAR-T therapy.

CONCLUSION
In the past decade, a variety of clinical trials of novel targeted agents have been conducted. Targeted immunotherapy has played a prominent role in it. Anti-GD2 chimeric mAb ch14.18 became the first drug approved by the US Food and Drug Administration (FDA) for first-line treatment of high-risk neuroblastoma in nearly 30 years, which was a breakthrough in the treatment of neuroblastoma. The widespread administration of anti-GD2 mAb has shown extraordinary antitumor efficacy, has greatly improved the survival rate of children with neuroblastoma and is presently the most promising drug in the treatment of neuroblastoma. The combination
of cytokines and anti-GD2 mAbs enhanced the synergy effect, leading to stronger cytotoxicity efficacy. The development of CAR-T therapy in neuroblastoma is still in an early stage. The current barriers of CAR-T are mainly target selection, antibody site screening, optimization of CAR structure, and enhancement of the migrating efficacy.

In addition, therapies targeting actionable mutations and abnormally activated signaling pathways are also a hot topic of current researches, due to the relatively high mutant frequency of recurrent neuroblastoma. Several novel agents and combinations of small molecular inhibitors have been tested preclinically and in early phase clinical trials. However, most results of clinical trials were disappointing, with limited antitumor activity and low rates of objective response. Moreover, it was usually unable to obtain tumor tissues at the time of relapse for acquiring information about mutations and abnormal pathways when children were enrolled in clinical trials. The ignorance of molecular pathways may restrict the efficacy of the drugs.

Despite a myriad of targets, the number of high-risk neuroblastomas for randomized clinical trials is limited. Early identification of patients with neuroblastoma at a very high risk of treatment failure has become a trend for early intervention by novel agents to avoid patients becoming refractory or relapsed cases. This requires a deeper understanding of the molecular biology of the relapsing process and resistant mechanism of neuroblastoma, and an early predictive model including molecular biomarkers.

Contributors LK proposed the study, and is responsible for the overall content as guarantor. WJ wrote the first draft. YW designed and performed the interpretation of the study and further drafts.

Funding This work was sponsored by Personnel Training Program for Distinguished Medical Young Scholar (2017, LK), New Hundred People Plan of Shanghai Health and Family Planning Commission (2017 BR052, LK), Distinguished Medical Young Scholar (2017, LK), New Hundred People Plan of China.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Not required for this review paper.

Data availability statement Data sharing is not applicable as there are no data sets generated and/or analysed for this study.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol 2015;33:3008–17.
2. Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009;45:2835–42.
3. London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International neuroblastoma risk group project. J Clin Oncol 2011;29:3286–92.
4. London WB, Bagatell R, Weigiel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on children's Oncology Group early-phase trials. Cancer 2017;123:4914–23.
5. Ladenstein R, Pötschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/ SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol 2017;18:500–14.
6. Schramm A, Köster J, Assenov Y, et al. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet 2015;47:872–7.
7. Elevated TF, Oldridge DA, Bernard V, et al. Relapsed neuroblastomas show frequent PAS-MAPK pathway mutations. Nat Genet 2015;47:864–71.
8. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by (123I)-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force, Br J Cancer 2011;102:1319–26.
9. Castellani MR, Chiti A, Seregini E, et al. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. experience of the National cancer Institute of Milan. Q J Nucl Med 2000;44:77–87.
10. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054–60.
11. Polishchuk AL, Dubois SG, Haas-Kogan D, et al. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 2011;117:4286–93.
12. Yangisawa M, Yoshimura S, Yu RK. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro 2011;3:AN20110006.
13. Cheung NK, Ostrovnya I, Kuk D, et al. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol 2015;33:755–63.
14. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397–411.
15. De Brouwer S, De Preter K, Kumps C, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4359–62.
16. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force, Br J Cancer 2011;102:1319–26.
17. Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682–94.
18. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971–4.
19. Mossé YP, Ladenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:900–5.
20. Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682–94.
21. De Brouwer S, De Preter K, Kumps C, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4359–62.
22. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013;3:308–23.
23. Faisal A, Vaughan L, Bavetsias V, et al. The Aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther 2011;10:2115–23.
24. Berry T, Luther W, Bhatnagar N, et al. The ALK(F1174L) mutant potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012;22:117–30.
25. Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014;142:164–75.
26. King D, Yeomanson D, Bryant HE. PI3K/Akt in the management of neuroblastoma. Expert Rev Hematol 2010;3:345–51.
27. Ribatti D. Anti-angiogenesis in neuroblastoma. Curr Rev Oncol Hematol 2013;8:212–21.
28 Peddinti R, Zeine R, Luca D, et al. Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 2007;13:3499–506.
29 Komuro H, Kaneko S, Kaneko M, et al. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 2001;127:739–43.
30 Modak S, Kushner BH, Basu E, et al. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: results of a phase II study. Pediatr Blood Cancer 2017;64:e26448.
31 Whittle SB, Patel K, Zhang L, et al. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs 2016;34:685–92.
32 Cheung NK, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012;1:477–86.
33 Lode HN, Schmidt MD, Seidel D, et al. Vaccination with anti-idiotypic antibody gangliodimab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother 2013;62:999–1010.
34 Shahbazi J, Liu PY, Atmadibrata B, et al. The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-myc expression and induce anticancer effects. Clin Cancer Res 2016;22:2534–44.
35 Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990;144:1382.
36 Federico SM, McCarrick H, Shulkin BL, et al. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. Clin Cancer Res 2017;23:6441–9.
37 Hezey A, Louis CU, Savoldo B, et al. CAR T-cells administered in combination with Lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther 2017;25:2214–24.
38 Yanik GA, Villablanca JG, Maris JM, et al. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant 2015;21:673–81.
39 Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324–34.
40 Kushner BH, Cheung IY, Modak S, et al. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res 2014;20:1375–82.
41 DuBois SG, Marchelliani A, Fox E, et al. Phase I study of the Aurora a kinase inhibitor Alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial. J Clin Oncol 2016;34:1368–75.
42 DuBois SG, Mosse YP, Fox E, et al. Phase II trial of Alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma. Clin Cancer Res 2018;24:6142–9.
43 Morandi F, Amoroso L, Dondero A, et al. Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma. Oncoimmunology 2018;7:e1468953.
44 Navid F, Sondel PM, Barfield R, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 2014;32:1445–52.
45 DuBois SG, Allen S, Bent M, et al. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer 2015;112:544–9.
46 Johnson K, McGlynn B, Saggio J, et al. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer 2011;57:1124–9.
47 Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children’s Oncology Group phase 1 Consortium study. Lancet Oncol 2013;14:472–80.
48 Pacenta HL, Macy ME. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther 2018;12:3549–61.
49 Bresler SC, Wood AC, Haglund EA, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3:108ra114.
50 Carpenter EL, Mossé YP. Targeting ALK in neuroblastoma–preclinical and clinical advancements. Nat Rev Clin Oncol 2012;9:391–9.
51 Iniguez AB, Alexe G, Wang EJ, et al. Resistance to epigenetic-targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling. Cancer Cell 2018;34:302–33.
52 Zage PE, Louis CU, Cohn SL. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer 2012;58:1099–105.
53 Kholodenko IV, Kalinovsky DV, Doronin II, et al. Neuroblastoma origin and therapeutic targets for immunotherapy. J Immunol Res 2018;2018:1–25.
54 Yong CSM, Dardalhon V, Devauch C, et al. CAR T-cell therapy of solid tumors. Immunol Cell Biol 2017;95:356–63.